secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031898
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics reports ONP-002 stable across wide temperature range, eliminating cold storage needs for concussion drug
--------------------------------------------------------------------------------

- ONP-002 shows >99% purity after 3-month stability testing at -20°C to 104°C.
- Drug-device combination designed for acute field-delivery without cumbersome cold chain logistics.
- Phase II clinical trial batch synthesis completed; no FDA-approved pharmaceutical treatment currently exists for concussion.
- Estimated 69 million concussions annually worldwide; drug targets intranasal delivery within minutes of injury.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224031898/0001493152-24-031898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224031898/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer